Skip to main content
. 2021 Nov 17;7(47):eabg9551. doi: 10.1126/sciadv.abg9551

Fig. 6. Multiomics drug repurposing identifies candidate therapeutic options and potential immuno-oncology targets in MM-PSN subgroups.

Fig. 6.

(A) Schema of the drug repurposing analysis. Somatic SNVs, CNAs, and gene expression profiles are annotated with the pan-cancer database CIViC to determine actionable alterations and the associated drugs. Additional drugs are identified through a machine learning approach matching patient profiles with sensitive cell lines in the databases GDSC and CCLE. (B) Drugs associated with each subgroup. The thickness of the edges represents the strength of the association, as defined by the essentiality of drug targets in MM cell lines according to CRISPR screenings (DepMap). (C) Targets of immuno-oncology therapies up- and down-regulated in each subgroup.